The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Monte Rosa Therapeutics, Inc
Neonc Technologies, Inc.
DualityBio Inc.
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Marengo Therapeutics, Inc.
Shanghai Public Health Clinical Center
TransThera Sciences (Nanjing), Inc.
Klus Pharma Inc.
Cybrexa Therapeutics
Salubris Biotherapeutics Inc
TransThera Sciences (Nanjing), Inc.
Evopoint Biosciences Inc.
Incyte Corporation
Gilead Sciences
Incyte Corporation
Masonic Cancer Center, University of Minnesota
Amgen